Swedish Orphan Bio Spon (SWTUY) Upgraded by Zacks Investment Research to Buy
Swedish Orphan Bio Spon (NASDAQ:SWTUY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday. The brokerage presently has a $17.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 18.88% from the company’s previous close.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Swedish Orphan Bio Spon (SWTUY) opened at 14.30 on Friday. The firm has a market capitalization of $3.85 billion and a P/E ratio of 48.15. The firm’s 50-day moving average is $15.52 and its 200-day moving average is $15.58. Swedish Orphan Bio Spon has a 52-week low of $10.25 and a 52-week high of $16.49.
COPYRIGHT VIOLATION NOTICE: “Swedish Orphan Bio Spon (SWTUY) Upgraded by Zacks Investment Research to Buy” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/28/swedish-orphan-bio-spon-swtuy-upgraded-by-zacks-investment-research-to-buy-2.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Swedish Orphan Bio Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio Spon and related companies with MarketBeat.com's FREE daily email newsletter.